Alnylam Pharmaceuticals, Inc. $ALNY Holdings Lifted by Fifth Third Bancorp

Fifth Third Bancorp increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7,433.9% during the first quarter, Holdings Channel.com reports. The fund owned 9,568 shares of the biopharmaceutical company’s stock after acquiring an additional 9,441 shares during the quarter. Fifth Third Bancorp’s holdings in Alnylam Pharmaceuticals were worth $3,166,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ALNY. MV Capital Management Inc. bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $25,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $29,000. HM Payson & Co. acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $27,000. Golden State Wealth Management LLC lifted its stake in Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 36 shares during the last quarter. Finally, Manchester Capital Management LLC boosted its holdings in Alnylam Pharmaceuticals by 600.0% during the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 72 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares in the company, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $267.47 on Monday. The firm’s 50 day moving average price is $294.16 and its two-hundred day moving average price is $320.56. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13. Alnylam Pharmaceuticals, Inc. has a twelve month low of $266.43 and a twelve month high of $495.55. The stock has a market cap of $35.71 billion, a price-to-earnings ratio of 73.08 and a beta of 0.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. The company had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company’s revenue for the quarter was up 96.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.44) earnings per share. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.26 EPS for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on ALNY shares. Truist Financial dropped their price target on Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating on the stock in a report on Monday, July 13th. Chardan Capital reissued a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 7th. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Finally, Wells Fargo & Company increased their price target on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a research report on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $455.31.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.